Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment

Next Previous
X
Search
Trial Profile

LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUX-Breast-1
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 28 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 24 May 2018 Planned End Date changed from 30 Apr 2018 to 15 Jun 2018.
    • 07 Mar 2018 Planned End Date changed from 26 Jan 2018 to 30 Apr 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top